Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human interferon-beta variants
- Development stage
- Preclinical
- Lead developer
- Heligenics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Recombinant human interferon-beta variants are a collection of engineered protein therapeutics developed by Heligenics as 'biobetters' for the treatment of multiple sclerosis (MS) and other autoimmune diseases. These variants are identified using the company's GigaAssay platform, which screens a comprehensive library of interferon-beta (IFN-β) mutations to find candidates with improved pharmacological properties, such as increased potency or reduced immunogenicity. The variants act as agonists of the interferon alpha/beta receptor (IFNAR), mimicking the natural cytokine's role in modulating the immune system and reducing neuroinflammation. The program, which includes a lead candidate designated as 'Biobetter A', is currently undergoing IND-enabling studies.
- Other names
- Recombinant Human Interferon-beta Variants (Biobetter A)Recombinant Human Interferon-beta Variants (Large Panel)Interferon-beta biobetter
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on recombinant human interferon-beta variants.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human interferon-beta variants.